Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

First Posted Date
2022-11-29
Last Posted Date
2024-11-27
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
25
Registration Number
NCT05628883
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma

First Posted Date
2022-11-23
Last Posted Date
2024-07-11
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
20
Registration Number
NCT05625594
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

First Posted Date
2022-11-22
Last Posted Date
2024-12-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
300
Registration Number
NCT05624554
Locations
🇺🇸

Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States

🇺🇸

Clermont Oncology Center ( Site 5224), Clermont, Florida, United States

🇺🇸

Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States

and more 94 locations

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects with Advanced/Metastatic Soft Tissue and Bone Sarcoma

First Posted Date
2022-11-18
Last Posted Date
2024-10-23
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT05621668
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

First Posted Date
2022-11-18
Last Posted Date
2023-10-04
Lead Sponsor
NYU Langone Health
Target Recruit Count
92
Registration Number
NCT05621759
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

First Posted Date
2022-11-18
Last Posted Date
2024-10-01
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
56
Registration Number
NCT05622318
Locations
🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

First Posted Date
2022-11-16
Last Posted Date
2024-08-20
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
20
Registration Number
NCT05618925
Locations
🇺🇸

Hoag Memorial Hospital, Newport Beach, California, United States

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

First Posted Date
2022-11-15
Last Posted Date
2022-12-15
Lead Sponsor
The Affiliated Hospital of Xuzhou Medical University
Target Recruit Count
23
Registration Number
NCT05616468
Locations
🇨🇳

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

First Posted Date
2022-11-04
Last Posted Date
2024-12-24
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
300
Registration Number
NCT05605899
Locations
🇫🇷

CHU Bordeaux-Hopital Haut-Leveque, Bordeaux, France

🇫🇷

Centre Leon Berard, Cedex Lyon 08, France

🇫🇷

CHU Dijon, Dijon, France

and more 87 locations

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

First Posted Date
2022-11-01
Last Posted Date
2024-11-06
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
3
Registration Number
NCT05601466
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy